December 20, 2010
Article
Preliminary results of two new targeted therapies, now in late-stage clinical trials, hold much promise for men with hormone-refractory, or castration-resistant, prostate cancer.
New developments in the treatment and management of prostate cancer.
December 09, 2010
New options for advanced prostate cancer mean prolonged remission.
Optune Plus Temodar and Keytruda May Result in Brain Tumor Control
ICI Response May Predict Relapse-Free Survival in Liver Cancer
Taking Time to ‘Smell the Roses’
Addressing Pros and Cons of CAR-T Cell Therapy in Melanoma